Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Recruiting now · Phase 2

Conditions studied: Triple Negative Breast Cancer

In brief

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.

Key facts

Study ID

NCT07283692

Run by

RenJi Hospital

People needed

46

Starts

2026-03-01

Expected to finish

2031-09-01

Last updated by the study team

2026-05-13

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, Aged ≥18 and ≤70 years
• Histologically confirmed triple negative breast cancer (ER<10%, PR<10%, and HER2 negative)
• Subjects with at least one evaluable lesion
• ECOG 0-1
• Adequate organ function

You may not qualify if…

• Metastatic disease (Stage IV)
• Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.